4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Marine Microorganisms: Cultivation Methods for Improving their Biotechnological Applications (MACUMBA)
Date du début: 1 août 2012, Date de fin: 31 juil. 2016,
Marine microorganisms form an almost untapped resource of biotechnological potential. However, its use is hindered by the low success rate of isolation of novel microorganisms and often by poor growth efficiency. Hence, the vast majority of marine microorganisms has not been cultivated and is often considered as ‘unculturable’. MaCuMBA aims at improving the isolation rate and growth efficiency of ...
Voir le projet
24
Participants partenaires
TERMINÉ
BlueGenics – From gene to bioactive product: Exploiting marine genomics for an innovative and sustainable European blue biotechnology industry (BlueGenics)
Date du début: 1 août 2012, Date de fin: 31 juil. 2016,
Marine organisms, in particular sponges and their associated microorganisms, are an inexhaustible source of novel bioactive (lead) compounds for biomedical application. Industrial exploitation of this natural resource using traditional approaches is, however, hampered, with a few exceptions, by unsolvable supply problems - despite of numerous efforts in the past. Therefore, there is, very likely, ...
Voir le projet
18
Participants partenaires
TERMINÉ
Academic-Industrial Training Network on Alpha-Synuclein-related Brain Diseases (NEURASYNC)
Date du début: 1 nov. 2009, Date de fin: 31 oct. 2013,
"Parkinson’s Disease (PD) is the second most common neurodegenerative disorder. It is characterized pathologically by the accumulation of aggregated conformations of the presynaptic protein alpha-synuclein (ASYN) in cytoplasmic inclusions termed Lewy Bodies (LBs). Furthermore, aberrant aggregated species of ASYN accumulate in various disease states, such as Multiple System Atrophy, Diffuse LB Dise ...
Voir le projet
11
Participants partenaires
TERMINÉ
Selected peptides as drug candidates directed to pain and neurodegeneration (PEP2BRAIN)
Date du début: 1 mars 2009, Date de fin: 28 févr. 2013,
...ral tests in rats. The same molecule was tested in a platform that screens potential pharmacological molecules/compounds for neurodegenerative diseases with positive results. The platform is owned by Bioalvo, SA (Portugal). The preliminary results so far obtained regarding efficacy and toxicology of the molecule are encouraging and the academic inventors and the industrial developers are committed ...
Voir le projet